Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer

Authors: János L. Tanyi, Sara Bobisse, Eran Ophir, Sandra Tuyaerts, Annalisa Roberti, Raphaël Genolet, Petra Baumgärtner, Brian J. Stevenson, Christian Iseli, Denarda Dangaj Laniti, Brian J. Czerniecki, Aikaterini Semilietof, Julien Racle, Alexandra Michel, Ioannis Xénarios, Cheryl Chiang, Dimitri Monos, Drew A. Torigian, Harvey Nisenbaum, Olivier Michielin, Carl H. June, Bruce L. Levine, Daniel J. Powell, David Gfeller, Rosemarie Mick, Urania Dafni, Vincent Zoete, Alexandre Harari, George Coukos, Lana E. Kandalaft - Science Translational Medicine 2018 cited by 441

= 10) until disease progression or vaccine exhaustion. A total of 392 vaccine doses were administered without serious adverse events. Vaccination induced T cell responses to autologous tumor antigen, which were associated with significantly prolonged survival. Vaccination also amplified T cell responses against mutated neoepitopes derived from nonsynonymous somatic tumor mutations, and this included priming of T cells against previously unrecognized neoepitopes, as well as novel T cell clones of markedly higher avidity against previously recognized neoepitopes. We conclude that the use of oxidized whole-tumor lysate DC vaccine is safe and effective in eliciting a broad antitumor immunity, including private neoantigens, and warrants further clinical testing.